ENSAIOS FARMACOCINÉTICOS MELHORADOS PARA DOMÍNIOS VARIÁVEIS SIMPLES DE IMUNOGLOBULINA

By using a suppressor protein or polypeptide with an exposed C-terminal end to bind pre-existing antibodies, the method addresses interference in ISVD assays, ensuring accurate quantification of ISVDs and related compounds in biological samples.

BR112018076569B1Active Publication Date: 2026-11-10ABLYNX NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112018076569
Authority / Receiving Office
BR · BR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-06-23
Filing Date
2017-06-21
Publication Date
2026-11-10
Estimated Expiration
2037-06-21

AI Technical Summary

Technical Problem

Pharmacokinetic assays for single variable immunoglobulin domains (ISVDs) face interference from pre-existing antibodies in biological samples, leading to inaccurate measurements due to protein-protein interactions at the C-terminal end of ISVDs.

Method used

Incorporating a suppressor protein or polypeptide with an exposed C-terminal end that binds pre-existing antibodies, preventing interference by ensuring they do not interact with the capture or detection agents, thereby stabilizing the assay.

Benefits of technology

The method reduces protein interference, providing accurate quantification of ISVDs and related compounds by ensuring pre-existing antibodies are bound by the suppressor, thus maintaining assay integrity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates generally to improved pharmacokinetic assays for measuring the levels of single variable immunoglobulin domains (also referred to herein as "isvs" or "isvds"), proteins and polypeptides comprising at least one isv (as further described herein) in biological samples.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 45 Enhanced Pharmacokinetic Assays for Single Variable Domains of Immunoglobulin

[0001] The present invention relates generally to improved pharmacokinetics for measuring the levels of single variable immunoglobulin domains (also referred to herein as ISVs or ISVDs) and proteins and polypeptides comprising at least one ISV (as further described herein) in biological samples.

[0002] In particular, the invention relates to improved methods for carrying out such tests.

[0003] Other aspects, embodiments, uses and advantages of the invention will become clear from the further description below.

[0004] In drug development, pharmacokinetic (PK) analysis of the drug is performed to determine the fate of the drug (e.g., distribution, absorption, and / or secretion) after administration to an animal or human. Generally, such analysis involves determining the presence, level, or concentration of the drug in a biological sample obtained from an individual (such as blood, serum, or plasma), often at various points in time.

[0005] For this purpose, pharmacokinetic assays are used, and the methods and techniques for performing such assays are generally known to the specialist. Generally, the usual methods for performing Petition 870260039857, dated 04 / 29 / 2026, page 10 / 106 2 / 45 Pharmacokinetic assays involve the steps of contacting the sample with a capture agent that can bind the compound to be measured (e.g., under conditions such that said capture agent can capture the compound to be measured) and then determining the amount of the compound to be measured that was captured by the capture agent (which serves as a measure of the amount of compound in the sample). In practice, a sandwich configuration is often used, in which the capture agent is immobilized on a surface (such as the surface of a chip or multi-well plate) and the amount of compound captured by the capture agent is determined by the addition of a detection agent that can generate a signal that can be detected and / or measured. In quantitative PK assays, the strength of this signal is a measure of the amount of the compound to be measured that was captured by the capture agent, which in turn is a measure of the amount of compound to be measured in the initial sample.

[0006] As mentioned, the appropriate techniques for performing these assays (such as ELISA, the MSD platform from MesoScale Diagnostic LLC, the Gyrolab™ platform from Gyros AB, and the Singulex™ platform from Merck Millipore) are well known in the art. Frequently, the capture agent is an antibody (polyclonal, but preferably monoclonal) that can bind to (and has often been specifically raised against) the compound to be measured (although the present invention also provides for the use of other capture agents, such as ISVDs or target antibodies). Petition 870260039857, dated 04 / 29 / 2026, page 11 / 106 3 / 45 of the compound to be measured (see for example Figures 2, 4 and 5 and the additional description here). The detection agent can be any suitable agent that can be used to provide a detectable / measurable signal. For example, the detection agent could be an antibody (preferably monoclonal) against the compound to be measured that has been conjugated with a detectable label or marker. Some non-limiting examples that are frequently used in practice include fluorescent markers, a label or marker that can be detected using electrochemiluminescence techniques (such as the ruthenium-based SULFO-TAG™ markers used as part of the MSD platform), or horseradish peroxidase or another enzyme that can convert a substrate into a detectable / measurable product.As is well known for sandwich immunoassays (such as sandwich ELISA), it is also possible to use, as a detection agent, a combination of a detection antibody that binds to the compound to be measured and a secondary antibody linked to an enzyme that can catalyze the conversion of a substrate into a detectable product. For a general description of these and similar techniques, reference is made to standard manuals, as well as, for example, O'Kennedy et al., Biochemical Education 18(3), 1990, and Gan and Patel, Journal of Investigative Dermatology. (2013), 133, and 2. doi: 10.1038 / jid.2013.287 (online publication).

[0007] Figures 1 to 6 schematically show some preferred, but not limiting, configurations for the Petition 870260039857, dated 04 / 29 / 2026, p. 12 / 106 4 / 45 conducting pharmacokinetic tests of the type specified in this application.

[0008] In figure 1 and the other figures, the invention is illustrated using a bivalent ISVD construction (i.e., comprising two ISVDs which are each represented by an oval shape and which in the illustrated constructions are linked together by a suitable ligand represented by a solid line) as the compound to be measured (indicated as (1) in each of figures 1 to 6).It should be noted that, as described herein, the choice of this bivalent ISVD construct is for illustrative purposes only and that the invention can generally be applied to any assay for determining the quantity in a biological sample of any protein, polypeptide or other compound or construct comprising at least one ISVD (and in particular, as described herein, comprising at least one ISVD with an exposed C-terminal end, i.e., such that said C-terminal end – and by extension, the protein, polypeptide, compound or construct – is at risk of being bound by pre-existing antibodies in the sample while the assay is being performed). Other examples of such proteins, polypeptides, compounds or constructs will be clear to a person skilled in the art based on the present disclosure and, as mentioned herein, for example, include monovalent, bivalent, trivalent, biparatopic and / or trispecific ISVD polypeptides or constructs (e.g., Petition 870260039857, dated 04 / 29 / 2026, p. 13 / 106 5 / 45 in Example 1, ALX-0171, a construction of Trivalent nanobody against RSV).

[0009] In the assay of Figure 1, a monoclonal antibody (2), linked to a solid support (4) via a covalent bond or other suitable ligand or immobilization technique (3) is used to capture the compound to be measured (1). After removing any unbound compound (1) (i.e., by washing), the amount of compound (1) captured by the monoclonal (2) is determined by adding the detection agent, which in the configuration shown in Figure 1 is a monoclonal antibody (5) conjugated with a detectable marker (6) via a ligand (7) or other suitable conjugation technique (such as a streptavidin-biotin pair). Any excess detection agent is then removed (i.e., again by washing), after which the amount of detection agent bound to the compound (1) captured by the capture agent, using the signal provided by the detectable marker (6) is determined.

[0010] The assay setup shown in figure 2 is essentially the same as the setup shown in figure 1, except that instead of a monoclonal antibody against compound (1), the target (8) of compound (1) is immobilized on the solid support (4) (i.e., using the ligand (3).

[0011] In the assay setup shown in figure 3, the compound to be measured (1) is again captured by the monoclonal antibody (2) bound to the solid support (4), but Petition 870260039857, dated 04 / 29 / 2026, p. 14 / 106 6 / 45 In this case, the assay is performed in the presence of the (soluble) target (8) of the nanobody construct (1) to be measured, and the detection agent (comprising the monoclonal marker (5) and detectable (6), linked by the ligand (7)) is directed to the target (8) instead of the compound (1).

[0012] The assay setup shown in Figure 4 is essentially the same as the setup shown in Figure 3, except that an “ISVD anti-ISVD (9) (e.g., a Nanobody directed against VHH structure sequences) is used as the capture agent instead of a monoclonal antibody.

[0013] The assay setup shown in figure 5 is essentially the same as the setup shown in figure 2, except that instead of the monoclonal antibody (5), a combination of a biotinylated anti-ISVD (10) ISVD (11) and horseradish peroxidase (HRP) labeled streptavidin (12) is used as the detection agent.

[0014] The assay setup shown in figure 6 is essentially the same as the setup shown in figure 2, except that the detection agent, a combination of a detection antibody (13) and a labeled secondary antibody (5) / (6) / (7) are used.

[0015] The appropriate test settings, in addition to those explicitly described in the figures, will be clear to a person skilled in the art based on the disclosure and examples presented here and, as mentioned, the tests. Petition 870260039857, dated 04 / 29 / 2026, page 15 / 106 7 / 45 shown in Figures 1 to 6 and similar tests can be performed using generally known techniques and methodology that will be clear to a person skilled in the art based on this disclosure.

[0016] In document WO 12 / 175741, it is described that protein interference can occur in some assays (such as, for example, ADA immunoassays) that are used to analyze biological samples (such as blood samples including whole blood, serum and plasma, ocular fluid, bronchoalveolar fluid / BALF, cerebrospinal fluid or other biological fluid samples) containing ISVD, and that such protein interference can give rise to a specific signal in some of these assays and / or for some of these samples. Document WO 12 / 175741 also mentions that such protein interference can occur not only in samples that are obtained from individuals who have been treated with an ISVD and / or to whom an ISVD has been administered (such as patients or individuals in clinical trials), but also in samples from individuals who have never received an ISVD.As further mentioned in document WO 12 / 175741, this indicates that such interference is likely due to a specific protein-protein interaction with pre-existing proteins, rather than with any emergent ADAs. Document WO 12 / 175741 further indicates that these interfering factors are likely (pre-existing) IgGs that can bind to the C-terminal end of a variable domain, if present. Petition 870260039857, dated 04 / 29 / 2026, p. 16 / 106 8 / 45 exposed (see, for example, also WO 13 / 024069, Holland et al. J. Clin. Immunol. 2013, 33 (7): 1192-203 and WO 2015 / 173325).

[0017] As pharmacokinetic assays generally involve the use of serum samples (i.e., from individuals to whom an ISVD or a drug comprising an ISVD has been administered), it is possible that such “pre-existing antibodies” against an exposed C-terminal end of an ISVD, when present in such samples, may interfere with said assay. With this in mind, the invention aims to provide improved pharmacokinetic assays and methods for performing the same in which such interference (and / or the risk of such interference occurring) is reduced.

[0018] Generally, the invention solves the problem of possible protein interference by performing the assay in the presence of (a sufficient amount of) a “suppressor”, that is, a protein or polypeptide to which any pre-existing antibodies present in the sample can bind. As a result, interfering factors are not (or are no longer) able to interfere with the association between the capture agent, the compound to be measured and the detection agent (in a way that could affect or distort the assay).

[0019] Generally, as further described herein, the suppressors used herein are ISVDs or proteins and polypeptides comprising an ISVD with an exposed C-terminal end, wherein the ISVDs, protein or polypeptides Petition 870260039857, dated 04 / 29 / 2026, page 17 / 106 9 / 45 are such that they cannot yet be captured by the capture agent and are not bound by the compound being measured or by the detection agent.

[0020] Thus, in a first aspect, the invention relates to a method for determining the quantity and / or concentration in a sample of at least one ISVD, or of a protein, polypeptide or other compound or construct comprising at least one ISVD (wherein the protein, polypeptide or other compound or construct is as described herein), which method comprises the steps of: a) contact the sample with a capture agent, such that the ISVD, protein or polypeptide is captured by said capture agent; b) contacting the ISVD, a protein or polypeptide captured by the capture agent, with a detection agent, such that said detection agent binds to the ISVD, a protein or polypeptide captured by the capture agent; (c) generate a signal corresponding to the amount of detection agent bound to the ISVD, a protein or polypeptide captured by the capture agent, wherein said method is performed in the presence of a suppressor, said suppressor being a protein or polypeptide to which pre-existing antibodies can bind (i.e., specifically bind), but to which the capture agent (essentially) does not bind. Petition 870260039857, dated 04 / 29 / 2026, p. 18 / 106 10 / 45 can connect. For this purpose, the suppressor is preferably as described here.

[0021] As will become clear to a person skilled in the art based on this disclosure, generally, in the method described above, the sample will be a sample of a biological fluid that is known to contain and / or suspected to contain pre-existing antibodies that are directed against the exposed C-terminal end of an ISVD. In particular, the sample will be a sample of a biological fluid that is known to contain and / or suspected to contain pre-existing antibodies that are directed against the exposed C-terminal end of an ISVD (and in particular against a Nanobody or other ISVD that is or was derived from a VH or VHH domain).

[0022] The sample will also contain (at least one) ISVD, protein, polypeptide, compound or construct to be measured. In particular, the said ISVD, protein, polypeptide, compound or construct to be measured may be an ISVD, protein, polypeptide, compound or construct that has been administered to the individual from whom the sample was obtained, for example, as part of a clinical trial or for therapeutic or diagnostic purposes. In one aspect, the sample was obtained in order to determine the pharmacological properties of the ISVD, protein, polypeptide, compound or construct to be measured and, in particular, its pharmacokinetic properties (e.g., its PK or serum half-life parameters). Petition 870260039857, dated 04 / 29 / 2026, page 19 / 106 11 / 45

[0023] The sample may be any desired and suitable sample of a biological fluid obtained from an individual, such as a sample of whole blood, serum, plasma, lymphatic fluid, ocular fluid, bronchoalveolar fluid / BAL, cerebrospinal fluid or other biological fluid (such as sputum or nasal washes); and, in particular, a sample of whole blood, serum or plasma. Said sample may also have been suitably prepared for use in the assay of the invention (for example, by suitable dilution or extraction methods, if appropriate, and / or by one or more suitable pretreatment steps known per se in the art, such as a suitable acid dissociation step).In practice, it is generally known that the sample will contain, or is expected to contain, a certain amount of the ISVD, protein, polypeptide compound or construct to be measured, for example because – as mentioned here – the sample in question was obtained from an individual to whom the ISVD, protein, polypeptide compound or construct in question was administered.

[0024] The ISVD compound, protein, polypeptide or construct to be measured using the assay of the invention may comprise or consist essentially of a monovalent ISVD or may be a protein, polypeptide, compound or construct comprising or consisting essentially of one or more (such as one, two, three, four or five) ISVDs. These may include, for example, proteins, polypeptides, compounds or constructs comprising at least one (such as one, two Petition 870260039857, dated 04 / 29 / 2026, page 20 / 106 12 / 45 or three) ISVDs, and optionally one or more other units or entities, suitably connected to each other, for example via direct chemical bonding, or using one or more suitable ligands. Reference is made to the additional description and prior art cited herein.

[0025] In one aspect, in such proteins, polypeptides, compounds or constructs, at least one of the ISVDs present will be directed against a therapeutically relevant target. In a specific aspect, such proteins, polypeptides, compounds or constructs will have a half-life in humans (expressed as t1 / 2-beta) of at least one day, such as at least three days, for example up to 5 days or more. To this end, the protein, polypeptide, compound or construct may contain a binding unit, domain or linking unit that provides at least one therapeutic ISVD with an increased half-life. This may be, for example, an ISVD against a (human) serum protein such as against (human) serum albumin. Reference is made to the further disclosure presented herein.

[0026] In another aspect, such proteins, polypeptides, compounds or constructs comprise at least one ISVD against a serum protein (human), such as serum albumin (human), to which further disclosure presented herein is again referenced. Generally, in this aspect, the protein, polypeptides, compound or construct will generally contain at least one therapeutically active moiety. Petition 870260039857, dated 04 / 29 / 2026, page 21 / 106 13 / 45 active, binding domain or binding unit, such as one or more binding domains or binding units (including again ISVDs such as Nanobodies) against one or more therapeutically relevant target(s). In such proteins, polypeptides, compounds or constructs, the serum albumin-binding ISVD will generally be used to increase the half-life of one or more therapeutic moieties or entities. Again, such proteins, polypeptides, compounds or constructs will have a half-life in humans (expressed as t1 / 2beta) of at least one day, such as at least three days, for example 5 days or more.

[0027] The proteins and polypeptides referred to herein are preferably fusion proteins. In one aspect, the proteins and polypeptides comprise or consist essentially of ISVD, optionally linked via one or more suitable linkers.

[0028] Generally, in the invention, the ISVD, protein, polypeptide, compound or construct to be measured will be such that it comprises at least one ISVD (such as an ISVD against a therapeutic target and / or an ISVD with a prolonged half-life, such as an ISVD against a serum protein) that is susceptible and / or at risk of binding to pre-existing antibodies and, in particular, to pre-existing antibodies against the exposed C-terminal end of said ISVD. Frequently, said ISVD will be at the C-terminal end of the protein, polypeptide, compound or construct to be measured. Petition 870260039857, dated 04 / 29 / 2026, p. 22 / 106 14 / 45

[0029] In a particular aspect, the ISVD, protein, polypeptide, compound or construct to be measured shall comprise at least one heavy chain ISVD (e.g., an ISVD that is a Nanobody or another ISVD that is or was derived from a VHH or VH domain, as further described herein), which is susceptible and / or at risk of being bound by pre-existing antibodies and, in particular, by pre-existing antibodies against the exposed C-terminal end of said ISVD. Frequently, said heavy chain ISVD will be at the C-terminal end of the protein, polypeptide, compound or construct to be measured.

[0030] One or more ISVDs present in the ISVD, protein, polypeptide, compound or construct to be measured may also be sequence optimized for reduced binding by pre-existing antibodies, for example by possessing a C-terminal extension (as described for example in WO 12 / 175741) and / or possessing structural mutations that reduce binding by pre-existing antibodies (see WO 2015 / 173325).

[0031] For ISVDs, proteins, polypeptides, compounds or constructs that can be measured using the methods and assays of the invention, further reference is made to the disclosure and prior art cited herein.

[0032] The suppressor used may be any ISVD that has an exposed C-terminal end, or any protein, polypeptide, compound or construct comprising at least one ISVD with an exposed C-terminal end (and, Petition 870260039857, dated 04 / 29 / 2026, page 23 / 106 15 / 45 in particular, with an ISVD at its C-terminal end). For example, in a specific but not limiting aspect, the suppressor comprises two (or may even comprise three) ISVDs linked to each other using a suitable ligand known per se.

[0033] The suppressor will be chosen in such a way that any pre-existing antibodies in the sample can (specifically) bind to it, in particular with an affinity that is as described here.

[0034] To ensure that pre-existing antibodies will bind to the suppressor (i.e., instead of the protein, polypeptide, compound or structure to be measured), the suppressor may be chosen such that the affinity for binding interaction between the suppressor and the pre-existing antibodies is higher / better (as described herein) than the affinity for binding interaction between the protein, polypeptide, compound or construct to be measured and the pre-existing antibodies (for example, and without limitation, when the protein, polypeptide, compound or construct to be measured contains a C-terminal extension and / or structural mutations that reduce binding by pre-existing antibodies, this can be easily achieved by choosing a suppressor that does not contain such a C-terminal extension and such mutations).

[0035] Thus, in a non-limiting aspect, the suppressor used in the methods of the invention is chosen in such a way that Petition 870260039857, dated 04 / 29 / 2026, page 24 / 106 16 / 45 the affinity for the binding interaction between the suppressor and pre-existing antibodies is at least 10 times (as well as at least 100 times) higher / better (as described herein) than the affinity for the binding interaction between the protein, polypeptide, compound or construct to be measured and pre-existing antibodies (generally, in the context of the present application, by way of illustration, an affinity of 10nM is considered 10x better or “higher” than an affinity of 100nM).

[0036] As further described herein, for the purposes of comparing affinities as described in the preceding paragraphs, the affinity for the binding interaction between the suppressor and antibody 21-4 (which may be used as a template / substitute for pre-existing antibodies) may be compared with the affinity for the binding interaction between the protein, polypeptide, compound or construct to be measured and antibody 21-4. Thus, in a specific but not limiting aspect of the methods of the invention, the suppressor may be chosen such that the affinity for the binding interaction between the suppressor and antibody 21-4 is better / superior (as defined herein, and in particular, at least 10 times better, at least 100 times better) than the affinity for the binding interaction between the protein, polypeptide, compound or construct to be measured and antibody 21-4. Petition 870260039857, dated 04 / 29 / 2026, page 25 / 106 17 / 45

[0037] Another way to ensure that pre-existing antibodies bind to the suppressor (e.g., instead of the protein, polypeptide, compound, or construct to be measured) is to use an appropriate excess (such as at least 10 times the excess, for less than 100 times the excess) compared to the amount of protein, polypeptide, compound, or construct to be measured that is (maximally) expected to be present in the sample. Generally, such an appropriate excess should be used when (it is expected that) the affinity for the binding interaction between the suppressor and pre-existing antibodies is approximately the same as, or even worse / lower than, the affinity for the binding interaction between the protein, polypeptide, compound, or construct to be measured and pre-existing antibodies (generally, in the context of the present application, by way of illustration, an affinity of 100 nM is considered 10 times worse or lower than an affinity of 10 nM).Also, an appropriate excess of suppressor may also be used when (it is expected that) the affinity for the binding interaction between the suppressor and pre-existing antibodies is better than the affinity for the binding interaction between the protein, polypeptide, compound or construct to be measured and pre-existing antibodies.

[0038] Preferably, the suppressor (and in particular the ISVD in the suppressor to which pre-existing antibodies are intended to bind) has no sequence optimization to reduce binding by pre-existing antibodies. Petition 870260039857, dated 04 / 29 / 2026, p. 26 / 106 18 / 45 existing. For example, it may terminate with the VTVSS sequence without any C-terminal extension and, preferably, also does not contain mutations intended to reduce binding by pre-existing antibodies. In addition, an ISVD or protein, polypeptide, compound or construct comprising an ISVD with an exposed C-terminal end may be used, provided it does not interfere with the assay (e.g., because it may bind to and / or is bound to any of the other components used in the assay).

[0039] In practice, with respect to the (possible) binding of the suppressor to pre-existing antibodies and also with respect to the selection of a suitable suppressor to which pre-existing antibodies can bind, it should be noted that it is possible that the pre-existing antibodies in a sample may form a heterogeneous polyclonal population and it is also possible that the pre-existing antibodies (and their affinities for ISVDs) may sometimes also differ from sample to sample and / or from individual to individual.

[0040] To explain this, in the invention, the binding (e.g., affinity) by the mouse monoclonal antibody clone “21-4-3” (also referred to herein as “21-4” or “ABH0015”) can be used as a template / tool ​​to determine whether a candidate suppressor will be bound by pre-existing antibodies or not. 21-4-3 (and the hybridoma that produces it, also referred to as ABH0015) known from WO 12 / 175741 (see pin 19, lines 328) where described and used as a substitute / template for Petition 870260039857, dated 04 / 29 / 2026, p. 27 / 106 19 / 45 determine whether a protein or polypeptide containing an ISVD with an exposed C-terminal end has a tendency to undergo protein interference (e.g., being bound by pre-existing antibodies that may be present in a biological sample that was obtained from an individual). Document WO 12 / 175741 also provides the VH and VL sequences of ABH0015 (see WO 12 / 175741, SEQ ID Nos: 35 and 36). In the present patent application, they are represented by the SEQ IP Nos. : 6 and 7. As mentioned in Example 7 of document WO 12 / 175741, 21-4 was generated using hybridoma technology starting from a mouse immunized with the Nanobody construct of SEQ ID NO: 98 in WO 2006 / 122825, and a hybridoma cell line (named ABH0015) expressing 21-4 was deposited on June 4, 2012 with the BCCM, Ghent, Belgium, under accession number LMBP-9680-CB.As shown in Example 8 of WO 12 / 175741, monoclonal 21-4 recognizes the C-terminal of the Nanobody construct of SEQ ID NO: 98 in WO 2006 / 122825, whose C-terminal end consists of a Nanobody (humanized VHH) created against Von Willebrand factor (vWF), and can be used to predict whether an ISV has a tendency to undergo specific protein interference. In Example 9, WO 12 / 175741 also provides a protocol in which ABH0015 is used to predict / determine whether a protein or polypeptide (in particular, a protein or polypeptide comprising an ISVD with an exposed C-terminal end) would or would not have a tendency to undergo protein interference. Petition 870260039857, dated 04 / 29 / 2026, page 28 / 106 20 / 45 (that is, being linked to pre-existing antibodies that may be present in a biological sample obtained from an individual).

[0041] In the present invention, the 21-4 linkage can be used as a surrogate to measure / determine whether a protein or polypeptide will be suitable for use as a suppressor or not (see also Example 5 here).

[0042] Generally, in the invention, a protein or polypeptide will be suitable for use as a suppressor if it is bound to 21-4 with an affinity (expressed as KD) better than 1 micromolar (μM), such as between 1000 and 1 nM, when determined using BIAcore according to the protocol described in Example 5 (for the sake of clarity and by way of non-limiting example, it is noted that generally, in the present description of the invention, an affinity of 1 nM is considered to be greater / better than an affinity of 1 micromolar / 1000nM).

[0043] As mentioned, when the methods of the invention intend to use a suppressor that has a higher / better affinity for pre-existing antibodies than the affinity that binds to pre-existing antibodies with the ISVD, protein, polypeptide, compound or construct to be measured, then preferably, the suppressor used will bind to 21-4 with an affinity that is a factor 10x (ten times) higher / better, preferably a factor 100x (100 times) higher / better, than the affinity that binds to the ISVD, protein, polypeptide, Petition 870260039857, dated 04 / 29 / 2026, page 29 / 106 21 / 45 compound or construct to be measured binds to 21-4 (again, in this context, by way of illustration, an affinity of 10 nM is considered 10 times greater than an affinity of 100 nM).

[0044] Thus, in one aspect, the invention relates to a method as described above, wherein the protein or polypeptide used as the suppressor is a protein or polypeptide that is bound by 21-4 with an affinity better than 1 micromolar (μM), such as between 1000 and 1 nM, when determined using BIAcore according to the protocol described in Example 5.

[0045] The suppressor must also essentially be unbound (or non-binding, other than specific binding) to the capture agent or the detection agent. In practice, this means that the affinity of the suppressor for the capture agent and for the detection agent (or vice versa, the affinity of the capture agent for the suppressor and the affinity of the detection agent for the suppressor) must be less than 3 micromolar, preferably less than 10 micromolar, more preferably less than 50 micromolar, such as less than 100 micromolar (for the sake of clarity and by way of non-limiting example, it is noted that generally, in the present description of the invention, an affinity of 10 micromolar is considered worse than an affinity of 1 micromolar). Once a capture agent (candidate) and a detection agent (candidate) have been selected, Petition 870260039857, dated 04 / 29 / 2026, page 30 / 106 22 / 45 must be well within the craftsman's expertise to determine its affinity for a suppressor (candidate) and then select a suppressor that is suitable for use with the intended capture agent and detection agent.

[0046] Thus, in a further aspect, the invention relates to a method as described above, wherein the protein or polypeptide used as the suppressor is a protein or polypeptide that: (i) is bound by 21-4 with an affinity better than 1 micromolar (μM), such as between 1000 and 1 nM, when determined using BIAcore according to the protocol described in Example 5; and (ii) is bound by the intended capture agent and the intended detection agent with an affinity less than / worse than 3 micromolar, preferably less than 10 micromolar, more preferably less than 50 micromolar, such as less than 100 micromolar.

[0047] In the invention, the suppressor used can be a monovalent ISVD (such as a monovalent nanobody) or a fusion protein or construct comprising two or more (such as two or three) ISVDs (of which at least one has an exposed C-terminal end). In practice, the suppressor will generally be a polypeptide, protein (fusion) or construct that has an ISVD at its C-terminal end (which ISVD will then have an exposed C-terminal end by virtue of forming the C-terminal end of the polypeptide, protein or construct). Petition 870260039857, dated 04 / 29 / 2026, page 31 / 106 23 / 45

[0048] Since the suppressor must be able to bind to pre-existing antibodies, the VHH that forms the C-terminal end of the suppressor will preferably have no C-terminal extension (as described in WO 12 / 175741) nor any mutations that are intended to reduce binding by pre-existing antibodies (such as those described in WO 2015 / 173325).

[0049] Therefore, and preferably, the suppressor is a protein or polypeptide that has an ISVD (and preferably a Nanobody) at its C-terminal end and (the ISVD that forms the C-terminal end) the suppressor preferably has the amino acid sequence VTVSS (SEQ ID NO: 1) at its C-terminal end. The suppressor may, for example, suitably be a monovalent, bivalent, bispecific, trivalent or trispecific ISVD construct. Preferably, the suppressor is a monovalent Nanobody, a bivalent Nanobody construct (which may be monospecific or bispecific) or a trivalent Nanobody construct (which may be monospecific, bispecific or trispecific).

[0050] As shown in Figures 2 to 6, in some possible arrangements for the assay of the invention, the target for the compound to be measured (indicated as (8) in Figures 2 to 6) can be used as part of the capture agent or as part of the detection agent (or both). Consequently, although the ISVDs present in the suppressor can be directed against any targets, they should not be directed against the target of Petition 870260039857, dated 04 / 29 / 2026, p. 32 / 106 24 / 45 compound to be measured if the aforementioned target is used as part of the test.

[0051] Thus, in a further aspect, the invention relates to a method as described above, wherein the protein or polypeptide used as the suppressor is a protein or polypeptide containing at least one ISVD having an exposed C-terminal end, wherein the C-terminal end of said ISVD terminates with the C-terminal amino acid sequence VTVSS (SEQ ID NO: 1). Again, said suppressor preferably: (i) is bound by 21-4 with an affinity better than 1 micromolar (μM), such as between 1000 and 1 nM, when determined using BIAcore according to the protocol described in Example 5; and (ii) is bound by the intended capture agent and the intended detection agent with an affinity less than 3 micromolar, preferably less than 10 micromolar, more preferably less than 50 micromolar, such as less than 100 micromolar.

[0052] In another aspect, the invention relates to a method as described above, wherein the protein or polypeptide used as the suppressor is a protein or polypeptide that has an ISVD at its C-terminal end, wherein said C-terminal ISVD (and consequently, the protein or polypeptide used as the suppressor) terminates with the C-terminal amino acid sequence VTVSS (SEQ ID NO: 1). Again, said suppressor preferably: (i) is linked Petition 870260039857, dated 04 / 29 / 2026, p. 33 / 106 25 / 45 by 21-4 with an affinity better than 1 micromolar (μM), such as between 1000 and 1 nM, when determined using BIAcore according to the protocol described in Example 5; and (ii) is linked by the intended capture agent and the intended detection agent with an affinity less than / worse than 3 micromolar, preferably less than 10 micromolar, more preferably less than 50 micromolar, such as less than 100 micromolar.

[0053] A convenient way to use the suppressor in the methods of the invention is to dilute the samples to be tested (which, as mentioned above, may already have been subjected to one or more suitable pretreatment steps known per se, such as an acid dissociation step) with a suitable dilution buffer containing (an excess of) the suppressor before the capture step. In this way, the pre-existing antibodies in the sample will have been bound by the suppressor before the capture and detection steps, thus ensuring that they cannot interfere with the measurement and / or reading of the assay.

[0054] Other aspects, modalities, advantages and applications of the invention will become clear from the additional description presented here.

[0055] In this report:

[0056] The term “single variable immunoglobulin domain” (also referred to as “ISV” or “ISVD”) is generally used to refer to immunoglobulin variable domains (which can be heavy chain or light chain domains, including Petition 870260039857, dated 04 / 29 / 2026, page 34 / 106 26 / 45 VH, VHH, or VL domains) that can form a functional antigen-binding site without interaction with another variable domain (e.g., without a VH / VL interaction as required between the VH and VL domains of conventional 4-chain monoclonal antibodies). Examples of ISVDs will be clear to a person skilled in the art and, for example, include nanobodies (including a VHH, a humanized VHH, and / or a camelized VH, such as a camelized human VH), IgNAR domains, antibodies (single domain) (such as dAbs™) that are VH domains or that are derived from a VH domain, and antibodies (single domain) (such as dAbs™) that are VL domains or that are derived from a VL domain. Unless explicitly stated otherwise herein, ISVDs that are based on and / or derived from variable heavy chain domains (such as VH or VHH domains) are generally preferred. More preferably, unless explicitly stated otherwise in this document, an ISVD will be a Nanobody.

[0057] The term nanobody is generally as defined in WO 2008 / 020079 or WO 2009 / 138519 and therefore, in a specific aspect, generally denotes a VHH, a humanized VHH or a camelized VH (such as a camelized human VH) or generally an optimized VHH sequence (such as, for example, optimized for chemical stability and / or solubility, maximum overlap with known human structure regions and maximum expression). Note that the terms Nanobody or Petition 870260039857, dated 04 / 29 / 2026, p. 35 / 106 27 / 45 Nanobodies are trademarks of Ablynx NV and may therefore also be referred to as Nanobody® and / or Nanobodies®.

[0058] Generally, unless otherwise indicated herein, the ISVDs, nanobodies, polypeptides, proteins and other compounds and constructs referred to herein are intended for use in the prophylaxis or treatment of diseases or disorders in humans (and / or optionally also in warm-blooded animals and in particular in mammals). Thus, in general, the ISVDs, nanobodies, polypeptides, proteins and other compounds and constructs described herein are preferably such that they can be used as and / or can suitably be part of a (biological) drug or other pharmaceutically or therapeutically active agent and / or a pharmaceutical product or composition. Such a drug, agent or product is preferably such that it is suitable for administration to a human being, and for the prophylaxis or treatment of an individual in need of such prophylaxis or treatment or, for example, as part of a clinical trial.As further described herein, for this purpose, such drug or compound may contain other portions, entities or linking units in addition to the ISVDs provided by the invention (which, as also described herein, may be, for example, one or more other additional therapeutic units and / or one or more other portions that influence the pharmacokinetic or pharmacodynamic properties of the ISVD-based or nanobody-based biological material, such as its stocking). Petition 870260039857, dated 04 / 29 / 2026, page 36 / 106 28 / 45 life). Suitable examples of such other therapeutic or other moieties will be clear to those skilled in the art and, for example, may generally include any therapeutically active protein, polypeptide or other binding domain or binding unit, as well as, for example, modifications such as those described on pages 149 to 152 of WO 2009 / 138159. An ISVD-based or nanobody-based biological product is preferably a therapeutic or intended to be used as a therapeutic (which includes prophylaxis and diagnosis) and for this purpose contains at least one ISVD against a therapeutically relevant target (such as, for example, RANK-L, vWF, IgE, RSV, CXCR4, IL-23 or other interleukins, or their receptors, etc.).For some specific, but not limited, examples of such ISVD-based or nanobody-based biological products, reference is made to Examples 8 to 18 and also, for example, to the various applications of Ablynx NV (such as, for example, and without limitation, WO 2004 / 062551, WO 2006 / 122825, WO 2008 / 020079 and WO 2009 / 068627), as well as, for example (and without limitation), to applications such as WO 2006 / 038027, WO 2006 / 059108, WO 2007 / 063308, WO 2007 / 063311, WO 2007 / 066016 and WO 2007 / 085814. Also, as described herein, the additional portion may be an ISVD or Nanobody as described herein directed against a (human) serum protein such as (human) serum albumin, and such ISVD or Nanobody may also find therapeutic uses, in particular in and / or to prolong the half-life of one or more. Petition 870260039857, dated 04 / 29 / 2026, p. 37 / 106 29 / 45 Therapeutic ISVDs. Reference is made, for example, to documents WO 2004 / 041865, WO 2006 / 122787 and WO 2012 / 175400, which generally describe the use of serum albumin-binding nanobodies for half-life prolongation. Also, in the present description, unless explicitly stated otherwise herein, all terms mentioned herein have the meaning given in WO 2009 / 138519 (or the prior art cited in WO 2009 / 138519) or WO 2008 / 020079 (or the prior art cited in WO 2008 / 020079). Also, when a method or technique is not specifically described herein, it can be carried out as described in WO 2009 / 138519 (or in the prior art cited in WO 2009 / 138519) or in document WO 2008 / 020079 (or in the prior art cited in WO 2008 / 020079).Also, as described herein, any pharmaceutical product or composition comprising any ISVD or compound of the invention may also comprise one or more additional components known per se for use in pharmaceutical products or compositions (for example, depending on the intended pharmaceutical form) and / or for example one or more other compounds or active ingredients intended for therapeutic use (i.e., to provide a combination product).

[0059] In particular, the following terms have the same meaning as given hereafter, and / or where applicable may be determined in the manner described on pages 62 to 75 of WO 09 / 138519: agonist, antagonist, inverse agonist, uncharged nonpolar amino acid residue, Petition 870260039857, dated 04 / 29 / 2026, page 38 / 106 30 / 45 uncharged polar amino acid residue, charged polar amino acid residue, sequence identity, exactly the same and amino acid difference (when referring to a sequence comparison of two amino acid sequences), (in) essentially isolated form, domain, binding domain, antigenic determinant, epitope, against or directed against (an antigen), specificity and half-life. Furthermore, the terms modulation and modular, interaction site, specific for, blocking, blocked, blocking and essentially pH independent are as defined (and / or can be determined as described) on pages 74 to 79 of the Applicant's own WO 10 / 130832. Furthermore, when referring to the construct, compound, protein or polypeptide of the invention, terms such as monovalent, bivalent (or polyvalent), bispecific (or multispecific), and biparatopic (or multiparatopic) may have the meaning given in WO 09 / 138519, WO 10 / 130832 or WO 08 / 020079.

[0060] The term half-life as used herein in relation to an ISV, Nanobody, ISV-based Biological Products and Nanobodies or any other amino acid sequence, compound or polypeptide may generally be defined as described on page 57 of WO 08 / 020079 and as mentioned herein refers to the time required for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, in vivo, for example, due to degradation of Petition 870260039857, dated 04 / 29 / 2026, page 39 / 106 31 / 45 sequence or compound and / or clearance or sequestration of the sequence or compound by natural mechanisms. The in vivo half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any properly known manner, such as pharmacokinetic analysis. Suitable techniques will be clear to a person skilled in the art and, for example, can generally be as described in paragraph o) on page 57 of WO 08 / 020079. As also mentioned in paragraph o) on page 57 of WO 08 / 020079, the half-life can be expressed using parameters such as t1 / 2-alpha, t1 / 2-beta and the area under the curve (AUC). In this respect, note that the term half-life in this specific document refers to t1 / 2-beta or terminal half-life (where t1 / 2-alpha and / or AUC or both can be kept out of consideration).For example, reference is made to the Experimental section below, as well as to standard manuals such as Kenneth et al.: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and Peters et al., Pharmacokinetic Analysis: A Practical Approach (1996). Reference is also made to Pharmacokinetics, M. Gibaldi & D. Perron, published by Marcel Dekker, 2nd Rev. edition (1982). Similarly, the terms increased half-life or increased half-life, as defined in paragraph o) on page 57 of WO 08 / 020079, in particular, refer to an increase in t^-beta, with or without an increase in t^-alpha and / or AUC or both. Petition 870260039857, dated 04 / 29 / 2026, p. 40 / 106 32 / 45

[0061] When a term is not specifically defined in this document, it has the usual meaning in the art, which will be clear to a person versed in the art. For example, reference is made to standard manuals such as Sambrook et al, Molecular Cloning: A Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989); F. Ausubel et al, eds., Current Protocols in Molecular Biology, Green Publishing and Wiley Interscience, New York (1987); Lewin, Genes II, John Wiley & Sons, New York, NY, (1985); Old et al., Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2nd edition, University of California Press, Berkeley, CA (1981); Roitt et al., Immunology (6th ed.), Mosby / Elsevier, Edinburgh (2001); Roitt et al., Roitt's Essential Immunology, 10th Ed. Blackwell Publishing, United Kingdom (2001); and Janeway et al., Immunobiology (6th Ed.), Garland Science Publishing / Churchill Livingstone, New York (2005), as well as the general state of the art cited herein.

[0062] Also, as already indicated in this document, the amino acid residues of a Nanobody are numbered according to the general numbering for VH domains given by Kabat et al. (Sequence of proteins of immunological interest, US Public Health Services, NIH Bethesda, MD, Publication No. 91), as applied to the VHH domain of camelids in the article by Riechmann and Muyldermans, J. Immunol. Methods 2000 Jun 23; 240 (1-2): 185-195 (see for example figure 2 of this publication); or referred to here. According to this numbering, FR1 of a Petition 870260039857, dated 04 / 29 / 2026, p. 41 / 106 33 / 45 A nanobody comprising amino acid residues at positions 1-30, CDR1 of a nanobody comprising amino acid residues at positions 31-35, FR2 of a nanobody comprising amino acids at positions 36-49, CDR2 of a nanobody comprising amino acid residues at positions 50-65, FR3 of a nanobody comprising amino acid residues at positions 66-94, CDR3 of a nanobody comprising amino acid residues at positions 95-102, and FR4 of a nanobody comprising amino acid residues at positions 103-113.[In this regard, it is worth noting that, as is known in the art of VH domains and VHH domains, the total number of amino acid residues in each of the CDRs may vary and may not correspond to the total number of amino acid residues indicated by Kabat numbering (i.e., one or more positions according to Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed by Kabat numbering). This means that, in general, the numbering according to Kabat may or may not correspond to the actual numbering of amino acid residues in the actual sequence. Generally, however, it can be said that, according to Kabat numbering and regardless of the number of amino acid residues in the CDRs, position 1 in Kabat numbering corresponds to the beginning of FR1 and vice versa, position 36 according to Kabat numbering corresponds to the beginning of FR2 and vice versa, position 66 of...] Petition 870260039857, dated 04 / 29 / 2026, page 42 / 106 34 / 45 according to Kabat's numbering corresponds to the beginning of FR3 and vice versa, and position 103 according to Kabat's numbering corresponds to the beginning of FR4 and vice versa.

[0063] Alternative methods for numbering amino acid residues of Vh domains, which methods can also be applied analogously to camelid Vhh domains and nanobodies, are methods described by Chothia et al. (Nature 342, 877-883 (1989)), the so-called AbM definition and the so-called contact definition. However, in the present description, claims and figures, the numbering according to Kabat applied to Vhh domains by Riechmann Muyldermans will be followed, unless otherwise indicated.

[0064] It should also be noted that the Figures, Sequence Listing and Examples / Experimental Part are given only to further illustrate the invention and should not be interpreted or considered as limiting the scope of the invention and / or the appended claims in any way, unless explicitly stated otherwise.

[0065] The invention will now be described by means of the following preferred, non-limiting aspects, examples and figures, in which figures 1 to 6 schematically illustrate different configurations for carrying out pharmacokinetic assays of the type that can be used in the present invention. (in each case, the suppressor used in the invention is not shown).

[0066] Unless otherwise indicated, all steps performed in the Experimental Section below were carried out in accordance with the Petition 870260039857, dated 04 / 29 / 2026, page 43 / 106 35 / 45 manufacturer's instructions or otherwise using current conditions generally known to those skilled in the art. Example 1: Use of suppressants in a PK assay using the Mesoscale Discovery™ platform (MSD).

[0067] This example illustrates the use of a suppressor in pharmacokinetic assays used to determine the total concentration of nanobody-based (fusion) proteins in a human serum sample. In this example, the Mesoscale Discovery platform is used to determine the concentration of ALX-0171 (a trivalent nanobody construct against human respiratory syncytial virus; see WO 2010 / 139808) in human serum samples supplemented with different concentrations of ALX-0171. The assay setup is essentially represented schematically in Figure 1 (although ALX-0171 is a trivalent nanobody construct rather than the bivalent nanobody construct shown for illustrative purposes in Figure 1).

[0068] The suppressor used was a trivalent Nanobody construct (with an N-terminal HIS label and a C-terminal end that was the sequence of SEQ ID NO: 1 (i.e., without any C-terminal extension)), whose sequence is given in figure 7 as SEQ ID NO: 2.

[0069] A biotinylated and neutralizing mouse monoclonal ligand of Nanobody ALX-0171 was used as the capture agent (at 5.0 micrograms / mL in PBS / 0.1% of Petition 870260039857, dated 04 / 29 / 2026, p. 44 / 106 36 / 45 casein) and was immobilized on a 96-well Streptavidin-Gold multiarray plate. Human serum samples to be tested were diluted 50 times (first 5 times in PBS / 0.1% casein, then 5 times in 1000 mM acetic acid. After incubation for 60 minutes at room temperature, dilute 2 times in 1M Tris buffer pH 9.5 containing 4.0 micrograms of suppressant / ml). After overnight incubation at room temperature, samples are applied (in 50 microliter aliquots) to 96-well plates coated with the capture agent under standard conditions that allow ALX-0171 to be captured by the capture agent.

[0070] After incubation for 1 hour and washing, the detection agent (a mouse monoclonal ligand labeled with SULFO and neutralizing Nanobody ALX-0171) was added and allowed to bind to the ALX-0171 captured by the immobilized capture agent. After washing, the amount of electroluminescent signal in each well of the plate was measured within 10 minutes after the addition of the MSD readout buffer using a Sector Imager 2400.

[0071] It was found that neither the presence of any pre-existing antibodies in the human serum samples used, nor the presence or use of the suppressor as part of the assay, significantly affected the determination of the ALX-0171 concentration when ALX-0171 was added to the human serum samples at known concentrations between 987 pg / mL and 658537 pg / mL. These concentrations Petition 870260039857, dated 04 / 29 / 2026, page 45 / 106 37 / 45 fall within a general concentration range that, inter alia, should be representative of the concentrations of nanobody-based therapies expected to be found in serum samples obtained from humans during clinical trials involving nanobody-based therapy (e.g., to determine the pharmacokinetics of nanobody-based therapy), optionally after appropriate dilution. Example 2: Use of suppressants in an ELISA-based PK assay.

[0072] This example illustrates the use of a suppressor in ELISA-based pharmacokinetic assays used to determine the total active concentration of nanobody-based (fusion) proteins in a human serum sample.

[0073] In this example, the Nanobody is a bispecific construct targeted against the IL-6 receptor and human serum albumin (see WO 2008 / 020079 and WO 2009 / 095489). As is well known, the IL-6 receptor is known to occur in both a membrane-bound and a soluble form. The assay described in this example is capable of determining the total active concentration including the “free” Nanobody (i.e., not bound to the soluble IL-6 receptor that is present in the plasma sample used) and the Nanobody that is bound to the soluble IL-6 receptor that is present in the sample.

[0074] The test setup is essentially shown schematically in figure 4. Petition 870260039857, dated 04 / 29 / 2026, p. 46 / 106 38 / 45

[0075] The suppressor used was a monovalent nanobody (with an N-terminal HIS label and a C-terminal end that was the sequence SEQ ID NO: 1 without any C-terminal extension), whose sequence is given in figure 7 as SEQ ID NO: 3.

[0076] A bivalent nanobody that recognizes the structure(s) of nanobodies was used as a capture agent (at 3.0 micrograms / ml in BICA buffer) and was coated onto a Maxisorp C96 plate. The human serum samples to be tested were diluted 200 times (first 20 times in PBS / 0.1% casein, then 5 times in 1600 mM acetic acid. After incubation for 90 minutes at room temperature, they were then diluted 2 times in 1M Tris buffer pH 9.5 containing 0.5 micrograms / ml of human sIL-6 receptor and 4.0 micrograms of suppressor / ml). After 60 minutes of incubation at room temperature, the samples are applied (in 100 microliter aliquots) to 96-well plates coated with a capture agent under standard conditions that allow the anti-IL-6R nanobody to be captured by the capture agent.

[0077] After incubation for 1 hour and washing, a solution of the soluble IL-6 receptor (0.25 micrograms / ml) was added and incubated for 30 minutes at room temperature. After washing the plate, the detection agent (0.25 / ml of a mouse monoclonal antibody recognizing a different epitope on IL-6R than the Nanobody, allowing simultaneous antibody and Nanobody binding) was added, allowing binding to the IL-6R captured by the Nanobody, which itself is bound by the Petition 870260039857, dated 04 / 29 / 2026, p. 47 / 106 39 / 45 immobilized capture agent. After washing, 0.65 μg / mL of an HRP-labeled rabbit anti-mouse Ig was added and incubated for 30 minutes at room temperature. After washing, TMB substrate was added and the OD signal in each well was measured at 450 nm using 620 nm as a reference.

[0078] It was found that neither the presence of any pre-existing antibodies in the human serum samples used, nor the presence or use of the suppressor as part of the assay, significantly affected the determination of the concentration of the anti-IL-6R nanobody when it was added to human serum samples at known concentrations between 20.0 ng / mL and 1483.1 ng / mL. These concentrations fall within a general concentration range that, inter alia, should be representative of the concentrations of nanobody-based therapies expected to be found in serum samples obtained from humans during clinical trials involving nanobody-based therapy (e.g., to determine the pharmacokinetics of nanobody-based therapy), optionally after appropriate dilution. Example 3: Use of suppressants in a PK assay using the Mesoscale Discovery™ platform (MSD).

[0079] This example illustrates the use of a suppressor in pharmacokinetic assays used to determine the total active concentration of nanobody-based (fusion) proteins in a human serum sample. In this example, the Petition 870260039857, dated 04 / 29 / 2026, page 48 / 106 The 40 / 45 Mesoscale Discovery platform is used to determine the concentration of ALX-0761 (a trivalent nanobody construct against interleukin 17 A and F) in human serum samples mixed with different concentrations of ALX-0761.

[0080] The assay setup is essentially as schematically shown in Figure 3. The suppressor used was a monovalent nanobody (which has a C-terminal end with the sequence SEQ ID NO: 1 without any C-terminal extension), whose sequence is given in Figure 7 as SEQ ID NO: 4.

[0081] A biotinylated mouse monoclonal antibody that recognizes nanobody structures was used as the capture agent (at 1.0 microgram / mL in PBS / 0.1% casein) and immobilized on a 96-well multi-array Streptavidin-Gold plate. Human serum samples to be tested were diluted 100 times (first 50 times, then 2 times, both in PBS / 0.1% casein, containing 20.0 micrograms of suppressant / mL and 50.0 micrograms of anti-IL-17 mAb / mL, which was added to prevent any free IL-17 from interfering with the assay). After overnight incubation at room temperature, the samples are applied (in 50 microliter aliquots) to the 96-well plates coated with the capture agent under standard conditions that allow ALX-0761 to be captured by the capture agent.

[0082] After incubation for 1 hour and washing, a soluble IL-17A solution (2.0 micrograms / mL) was added and incubated. Petition 870260039857, dated 04 / 29 / 2026, page 49 / 106 41 / 45 if left for 1 hour at room temperature. After washing the plate, the detection agent (0.25 ml of a SULFO-labeled mouse monoclonal antibody binding to the IL-17A target) was added and allowed to bind to the IL-17A captured by the Nanobody, which itself bound to the immobilized capture agent. After washing, the amount of electroluminescent signal in each well of the plate was measured within 10 minutes after the addition of the MSD reading buffer using a Sector Imager 2400 reader.

[0083] It was found that neither the presence of any pre-existing antibodies in the human serum samples used, nor the presence or use of the suppressor as part of the assay, significantly affected the determination of the ALX-0761 concentration when ALX-0761 was added to human serum samples at known concentrations between 99.7 ng / mL and 3280.9 ng / mL. These concentrations fall within a general concentration range that, inter alia, should be representative of the concentrations of nanobody-based therapies expected to be found in serum samples obtained from humans during clinical trials involving nanobody-based therapy (e.g., to determine the pharmacokinetics of nanobody-based therapy), optionally after appropriate dilution. Example 4: Use of suppressants in an ELISA-based PK assay. Petition 870260039857, dated 04 / 29 / 2026, page 50 / 106 42 / 45

[0084] This example illustrates the use of a suppressor in the ELISA-based pharmacokinetic assay used to determine the concentration of nanobody-based (fusion) proteins in a rat plasma sample.

[0085] In this example, the Nanobody is targeted against Her3. The assay described in this example is capable of determining the concentration of ALX-0751 that is present in the sample.

[0086] The test setup is essentially shown schematically in figure 5.

[0087] The suppressor used was a bispecific Nanobody construct (which has a C-terminal end that has the sequence SEQ ID NO: 1 without any C-terminal extension), whose sequence is shown in figure 7 as SEQ ID NO: 5.

[0088] In this ELISA, HER3-ECD (1.5 micrograms / mL in 10:10 in Trizma NaCl buffer) is coated onto a Maxisorp C96 plate. Rat plasma samples to be tested are diluted 20-fold in PBS / 0.1% casein containing 200 micrograms of suppressant per mL. After 2 hours of incubation at 37°C, the samples are applied (in 50 microliter aliquots) to 96-well plates coated with the capture agent (target) under standard conditions that allow ALX-0751 to be captured by the capture agent.

[0089] After incubation for 1 hour and washing, a detection reagent (1 microgram / mL of biotinylated nanobody that recognizes the structure of the ALX-0751 nanobody) was added and incubated for 1 hour at room temperature. After the Petition 870260039857, dated 04 / 29 / 2026, page 51 / 106 43 / 45 washing, HRP-labeled streptavidin added and incubated for 30 minutes at room temperature. After washing, TMB substrate was added and the OD signal in each well was measured at 450 nm using 620 nm as a reference.

[0090] It was found that neither the presence of any pre-existing antibodies in the rat plasma samples used, nor the presence or use of the suppressor as part of the assay, significantly affected the determination of the concentration of the ALX-0751 nanobody when it was added to rat plasma samples at known concentrations between 24.9 ng / mL and 266.7 ng / mL. These concentrations fall within a general concentration range that, inter alia, should be representative of the concentrations of nanobody-based therapies expected to be found in plasma samples obtained from rats during preclinical studies involving nanobody-based therapy (e.g., for the purpose of determining the PK of nanobody-based therapy), optionally after appropriate dilution. Example 5: Protocol for determining affinity for 21-4.

[0091] Binding measurements were performed using a Biacore T100 using a CM5 sensor chip, with HBS-EP+ operating buffer, 25°C. 21-4 was captured via immobilized rabbit anti-mouse IgG, as it was found that the surface of directly immobilized mAb 21-4 could not be efficiently regenerated. The anti-mouse IgG used was a polyclonal rabbit anti-mouse IgG antibody that reacts with all Petition 870260039857, dated 04 / 29 / 2026, p. 52 / 106 44 / 45 subclasses of IgG, IgA, and IgM (GE Healthcare; Cat#BR-1008-38; Lot#10111487). Immobilization of anti-mouse IgG was performed using manual amine coupling with a 7-minute injection of EDC / NHS for activation and a 7-minute injection of 1M ethanolamine HCl pH 8.5 for deactivation (Biacore, amine coupling kit). Binding conditions are listed in Table I. Based on the immobilization level and MW of the proteins, the theoretical Rmax for binding of immobilized anti-mouse mAb21-4 IgG was ~13000RU (when one mAb21-4 molecule binds to one anti-mouse IgG molecule). Table I Flow Cell (FC) Protein Conc. (μα / ml) Contact Time (s) Flow Rate (μl / min) Immobilization Buffer Immobilization Level (RU) FC1 Anti-mouse IgG 30 420 5 10mM acetate pH 5.0 17305 (after deactivation: 13440) FC2 Anti-mouse IgG 30 420 5 10mM acetate pH 5.0 17020 (after deactivation: 12820)

[0092] The conditions used for the binding experiment (Biacore T100) using immobilized 21-4 are given in Figure 8. The anti-mouse IgG surface can be successfully regenerated after capturing the 21-4 mAb and injecting all samples (with a threshold increase to the baseline level after each regeneration). Petition 870260039857, dated 04 / 29 / 2026, page 53 / 106 45 / 45

[0093] The above protocol was used to generate the 21-4 affinity data for different suppressors as set out in Table II below. Table II Capture Suppressor ka (1 / Ms) kd (1 / s) Kd (M) 21-4 SEQ ID NO: 2 1.0E+04 3.0E-03 3.0E-07 SEQ ID NO: 3 6.7E+03 3.2E-03 4.8E-07 SEQ ID NO: 4 4.5E+03 4.0E-03 8.9E-07 SEQ ID NO: 5 9.5E+04 8.2E-04 8.6E-09 Petition 870260039857, dated 04 / 29 / 2026, page 54 / 106

Claims

1 / 3 CLAIMS 1. A method for determining the quantity and / or concentration in a sample of at least one single variable domain of immunoglobulin ISVD, or of a protein or polypeptide that includes at least one ISVD, the method being CHARACTERIZED by including the steps of: a) contacting the sample with a capture agent, such that the ISVD, protein or polypeptide is captured by said capture agent; b) contacting the ISVD, a protein or polypeptide captured by the capture agent with a detection agent, such that said detection agent binds to the ISVD, a protein or polypeptide captured by the capture agent;(c) generate a signal corresponding to the amount of detection agent bound to the ISVD, a protein or polypeptide captured by the capture agent, wherein said method is performed in the presence of a suppressor, said suppressor being a protein or polypeptide to which pre-existing antibodies against an exposed C-terminal end of the ISVD can bind, but to which the capture agent and the detection agent do not bind.

2. Method according to claim 1, CHARACTERIZED in that the protein or polypeptide used as the suppressor is a protein or polypeptide that is bound by the monoclonal antibody 21-4 produced by Petition 870260084021, dated 19 / 08 / 2026, page 8 / 13 2 / 3 hybridoma ABH0015 deposited at BCCM, Ghent, Belgium, under accession number LMBP-9680-CB (SEQ ID Nos: 6 and 7) with affinity between 1000 and 1 nM.

3. Method according to claim 1 or 2, CHARACTERIZED in that the protein or polypeptide used as a suppressor is a protein or polypeptide bound by the intended capture agent and the intended detection agent with an affinity of 3 to 100 micromolars.

4. Method according to any one of claims 1 to 3, CHARACTERIZED in that the suppressor is a single monovalent variable domain of immunoglobulin or a fusion or construct protein comprising no more than five, such as four, three, two or one single variable domain of immunoglobulin.

5. Method according to claim 4, CHARACTERIZED in that at least one of the unique variable immunoglobulin domains present in the suppressor has an exposed C-terminal end.

6. Method according to claim 5, CHARACTERIZED in that at least one of the unique variable immunoglobulin domains that has an exposed C-terminal end has the sequence VTVSS (SEQ ID NO: 1) at its C-terminal end.

7. Method according to claim 4 or 5, CHARACTERIZED in that at least the suppressor has a single variable immunoglobulin domain at its C-terminal end.

8. Method according to claim 7, CHARACTERIZED in that the single variable immunoglobulin domain at the C-terminal end of the suppressor (and, by extension, the complete suppressor) has the sequence VTVSS (SEQ ID NO: 1) at its C-terminal end. Petition 870260084021, dated 08 / 19 / 2026, p. 10 / 13